Loading...
01/10 19:55
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed strong financial performance, including a 15% revenue increase and solid EBITDA growth. The share repurchase plan indicates confidence in stock value, likely boosting investor sentiment. While regulatory risks exist, management's focus on product value and resilience in client engagement are reassuring. The positive financial metrics and strategic initiatives outweigh the hesitancy in client decision-making, suggesting a positive stock price movement. Given the market cap of $1.2 billion, the reaction is expected to be in the positive range of 2% to 8% over the next two weeks.
Revenue $115,900,000, an increase of 15% year over year.
Average Healthcare Services Clients 4,411, an increase of 70 from the prior quarter and 346 from the prior year.
Total Revenue per Average Healthcare Services Client $26,283, up 6% year over year and up 4% quarter over quarter.
Adjusted EBITDA $20,800,000, an increase of 16.7% year over year with an adjusted EBITDA margin of 18%.
Cash and Cash Equivalents $90,900,000, compared to $84,200,000 in the prior quarter.
Operating Cash Flow $14,900,000, up $15,600,000 year over year.
Free Cash Flow $7,500,000, up $13,700,000 year over year.
New Products: Products such as appointment readiness, post script engagement, and enhanced bill pay were developed and introduced with long-term value in mind and are already showing measurable impact across the network.
AI Integration: AI is being integrated across all aspects of the organization and current and future products.
Healthcare Services Clients: Average healthcare services clients increased to 4,411, up 70 from the prior quarter and 346 from the prior year.
Revenue Growth: Revenue was $115,900,000, an increase of 15% year over year.
Adjusted EBITDA: Adjusted EBITDA was $20,800,000, an increase of 16.7% year over year with an adjusted EBITDA margin of 18%.
Cash Position: Ended the quarter with $90,900,000 in cash and cash equivalents, up from $84,200,000 in the prior quarter.
Free Cash Flow: Free cash flow remains positive at $7,500,000 in the quarter, up $13,700,000 year over year.
Capital Allocation: With a strong balance sheet and growing free cash flow, the company is well positioned to allocate capital in ways that drive long-term shareholder value.
Revenue Outlook: Maintaining revenue outlook for fiscal year 2026 at a range of $472,000,000 to $482,000,000, with an updated adjusted EBITDA outlook of $85,000,000 to $90,000,000.
Regulatory Issues: Discussion on the proposed 'no handouts for drug advertisements act' which aims to eliminate the tax deduction for pharma companies on direct-to-consumer advertising. This could impact ROI for clients and may lead to a shift in advertising strategies.
Competitive Pressures: The market remains competitive, with ongoing challenges in decision-making from clients due to macroeconomic factors. Phreesia continues to focus on delivering value through product development to maintain its competitive edge.
Economic Factors: Conversations with clients indicate some hesitancy in decision-making due to the current economic environment, although Phreesia has shown resilience compared to others in the industry.
Supply Chain Challenges: No specific supply chain challenges were mentioned, but the overall economic environment may indirectly affect supply chain dynamics.
Client Engagement: Clients are increasingly cautious and are looking for trusted partners, especially after negative experiences with smaller VC-backed companies during the COVID boom.
Product Development: Phreesia is focused on continuously delivering valuable and scalable products that drive meaningful outcomes for patients and providers, including appointment readiness, post engagement, and enhanced bill pay.
AI Integration: AI is being integrated across all aspects of the organization and products, enhancing capabilities and driving value.
Capital Allocation: With a strong balance sheet and growing free cash flow, Phreesia is positioned to allocate capital towards profitable growth and value-enhancing opportunities.
Network Growth: Phreesia aims to grow its network through product-led growth.
Revenue Outlook: Maintaining revenue outlook for fiscal year 2026 at a range of $472 million to $482 million.
Adjusted EBITDA Outlook: Updating adjusted EBITDA outlook for fiscal year 2026 to a range of $85 million to $90 million, up from a previous range of $78 million to $88 million.
Average Healthcare Services Clients: Reiterating outlook for average healthcare services clients to reach approximately 4,500 in fiscal year 2026.
Revenue per Average Healthcare Services Client: Expecting total revenue per average healthcare services client to increase in fiscal year 2026 compared to fiscal year 2025.
Share Repurchase Plan: The board approved a share repurchase plan for up to 2,500,000 shares of common stock. The motivation for this repurchase authorization is to be opportunistic, particularly in response to market dislocations where the share price may reach a level that warrants intervention.
The earnings call presents strong financial metrics, including consecutive positive net income and increased cash flow, which are positive indicators. The Q&A session highlights a cautious but optimistic outlook, with plans for strategic investments and growth. While some management responses lack clarity, the overall sentiment is positive due to strong cash flow, margin expansion, and growth potential from acquisitions. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
The earnings call summary highlights strong financial metrics, optimistic guidance, and strategic acquisitions like AccessOne, which align with market expansion and product development goals. The Q&A session revealed analyst confidence in AI integration and new product offerings, despite some uncertainty regarding specific revenue details. The company's market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
The earnings call indicates strong financial performance with a 15% revenue increase and improved cash flow. Positive free cash flow and a strong cash position, along with a focus on product development, contribute to a positive outlook. Despite concerns about economic factors, management's resilience and strategic focus on growth and shareholder value are reassuring. The Q&A reveals no significant risks or uncertainties, and management's opportunistic share repurchase plan suggests confidence in future performance. Given the company's small-cap status, a positive stock price movement is expected.
The earnings call revealed strong financial performance, including a 15% revenue increase and solid EBITDA growth. The share repurchase plan indicates confidence in stock value, likely boosting investor sentiment. While regulatory risks exist, management's focus on product value and resilience in client engagement are reassuring. The positive financial metrics and strategic initiatives outweigh the hesitancy in client decision-making, suggesting a positive stock price movement. Given the market cap of $1.2 billion, the reaction is expected to be in the positive range of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
